ArticleJournal of hepatocellular carcinoma2024

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma.

Shadi Chamseddine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.